Oruka Therapeutics Inc（ABIO）财务数据ABIOOruka Therapeutics Inc

Evaluating the bottom line, ARCA Biopharma Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -20.05%, provide a clear picture of how effectively ABIO converts its operational activities into shareholder value.

In the context of the broader market, ABIO competes directly with industry leaders such as VTVT and BRNS. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ABIO's gross margin of N/A stands against VTVT's N/A and BRNS's N/A. Such benchmarking helps identify whether ARCA Biopharma Inc is trading at a premium or discount relative to its financial performance.